The abbreviations used are: OCTN, novel organic cation transporter; RT-PCR, reverse transcription-polymerase chain reaction; PGS, protein G-Sepharose; GST, glutathione S-transferase; ER, endoplasmic reticulum; PBS, phosphate-buffered saline; RT, room temperature; GFP, green fluorescent protein; ET A R, endothelin type A receptor; Ab, antibody. The accession number of rat cartregulin cDNA in the GenBank database is DQ119106.
INTRODUCTION
Carnitine (β-hydroxy-γ-trimethylamino butyrate) is essential for the transfer of long chain fatty acids from cytosol to mitochondrial matrix for subsequent β-oxidation to produce cellular energy [1] .
Its deficiency therefore impairs the ability to use the fatty acids as fuel, causing critical symptoms such as cardiomyopathy, skeletal muscle myopathy, and hypoglycemia [2] . Carnitine is also the precursor of acetylcarnitine, which is the major constituent of blood acylcarnitine [3] . A study using positron emission tomography has demonstrated that the blood acetylcarnitine is taken up into specific regions of the human brain [4] and the uptake in some of the regions is impaired in the brain of patients with chronic fatigue syndrome [5] . It has recently been reported in mice that the acetyl group of acetylcarnitine is used mainly for synthesis of neurotransmitters such as glutamate and aspartate in the brain [5] . Thus acetylcarnitine appears to play a role in the brain which is distinct from carnitine: this notion is consistent with the observations that acetylcarnitine but not carnitine possesses therapeutic potentials in the treatment of a wide variety of neurological disorders including chronic fatigue syndrome [27] , age-dependent memory loss [6, 7] and Alzheimer-type dementia [8, 9] . These data strongly indicate that a transporter for acetylcarnitine is present in the brain and plays an important role for brain function.
In many tissues of human [10, 11] , mouse [12, 13] , and rat [13] , carnitine is transported into cells by a plasma membrane organic cation transporter, OCTN2, in a Na + -dependent manner with a high affinity for carnitine (Km <10 μM). Rat OCTN2 is able to transport acetylcarnitine in addition to carnitine [13] and it is therefore likely that both human and mouse OCTN2 can also transport acetylcarnitine. However, levels of mRNA and protein for OCTN2 in the brain of humans or mice are very low or negligible [11, 12] . On the other hand, OCTN1 has been identified as a homologue to OCTN2 in various tissues of the above three mammals [12, 14, 15] . Mouse OCTN1 transports carnitine in a Na + -dependent manner with a low affinity for the substrate (Km > 400 μM) [14] , whereas human and rat OCTN1 appear to be inactive for carnitine transport [12, 15] . The transport activity of OCTN1 for acetylcarnitine has not been reported so far, but the activity is expected to be very low or absent based on transport activity for carnitine. In addition to OCTN1 and OCTN2, a third carnitine transporter, OCTN3, has been identified in the mouse [12] . Unlike OCTN2, mouse OCTN3 transports carnitine in a Na + -independent manner and the exclusive expression of OCTN3 in the kidney and testis limits its physiological function in the other tissues [12] . While the corresponding human and rat OCTN3 cDNAs have not yet been isolated, an expression of an OCTN3-like protein has recently been demonstrated in the human sperm and a human cell line by Western blot [16, 17] , and a rat OCTN3-like cDNA (NCBI Accession No. XM_220427) is predicted by a computer analysis of a locus of rat chromosome 10 (10q22). It is unknown that mouse OCTN3
or the human OCTN3-like protein can transport acetylcarnitine as well as carnitine. Thus there are at present no definitive candidate molecules for acetylcarnitine transporter in the brain.
Brain region-specific uptake of acetylcarnitine [4] , its involvement in the synthesis of neurotransmitters and its therapeutic potentials in neurological disorders encouraged us to speculate that a brain-specific acetylcarnitine transporter or a brain-specific regulator of acetylcarnitine transport is present to tightly regulate the uptake of acetylcarnitine in the brain. To get insights into molecular basis for acetylcarnitine transport into the brain, we attempted to isolate a brain-specific acetylcarnitine transporter. For this purpose, we screened a rat brain cDNA library by a plaque-hybridization method: for a probe, a DNA sequence was used which was conserved between OCTN1 and OCTN2. During the course of this study, we have isolated a new cDNA highly homologous to those of rat OCTNs. Therefore, the new clone appears to be a member of OCTN family. The new cDNA encodes a novel protein consisting of 146 amino acids with one transmembrane domain conserved between rat OCTN1 and OCTN2. The novel protein itself showed no transport activity for carnitine or acetylcarnitine when expressed in COS-7 cells, but it enhanced the transport activity of OCTN2 when co-expressed with OCTN2. The protein thus may be an up-regulator of OCTN2 and is tentatively designated cartregulin. We describe here the cDNA structure, the tissue distribution of its mRNA, the subcellular localization of cartregulin, and some of insights into the mechanism of enhancement of OCTN2 activity caused by the new protein. Denhardt's solution, 0.1% SDS, 30% formamide, 50 mM Na-phosphate buffer (pH 6.5), and 100 μg/ml denatured salmon sperm DNA. The filters were then washed three times with 0.5x SSC, 0.1% SDS for 30 min at 50 °C. Positive clones were plaque-purified and excised into pBK-CMV phagemids by infection with ExAssist helper phage (Stratagene). incubated for 1 h at RT with the primary Ab, and subsequently with the goat anti-rabbit IgG conjugated to horseradish-peroxidase labeled EnVision + polymer (DAKO) as described [18] . The antigen was visualized using BIOMAX film (Kodak) with ECL Plus kit and analyzed with a MCID densitometer (Imaging Research Inc. Canada). The Ab to cartregulin was isolated from the rabbit anti-serum raised to its C-terminus peptide (QKFFPSQFELYSPP) fused with GST using GSH-Sepharose column. The GST-fusion protein was produced in BL-21 gold E.coli (Stratagene)
MATERIALS AND METHODS

Materials
Northern blot and RT-PCR for cartregulin -
transformed with pGEX-5X-1 carrying the coding region of cartregulin cDNA. liquid-scintillation counter as described [11] .
Northern blot of OCTN2, OCTN1, and ET
Transport study in Xenopus oocytes -Freshly collected oocytes were washed in Ca into the cells were counted as described above. cRNA was synthesized using AmpliScribe T7 transcription kits (EPICENTRE, Madison, WI) and purified with RNeasy kits (QIAGEN).
RESULTS
Cloning of cartregulinc DNA.
We have screened a rat brain cDNA library (about 2 x 10 6 independent cDNA) with cross-hybridization using a probe from a highly conserved sequence between OCTN1 and OCTN2, and finally obtained 20 positive cDNA clones. Of the 20 cDNA clones, 12 clones encoded OCTN2, 7 clones OCTN1, and the remaining 1 clone a new sequence designated cartregulin.
Structure of cartregulin cDNA.
The cartregulin cDNA that consisted of 2926 nucleotides had a 5'-untranslated region of 233 bp and an open reading frame of 438 bp encoding a polypeptide of 146 amino acids. The coding region was followed by a long 3'-untranslated region of about 2300 bp including a polyadenylation signal (AATAAA) at the end of the sequence (Fig. 1 ). Homology analysis indicated that the first ~ 0.6 kb sequence (1-626) of cartregulin cDNA was unique because no sequences identical to this part were found in any databases of rat cDNA and genome DNA available at present. However, the part (240-626) of the first 0.6 kb sequence was highly homologous to the corresponding region (78-464) of rat OCTN1 cDNA (AF169831) with 85% identity or the region (107-493) of rat OCTN2 cDNA (AF110416) with 90% identity. Further homology analysis ( Fig. 1 ) revealed that the middle ~1.5 kb sequence (627-2119) of cartregulin was essentially identical to the sequence of 350-1839 of a putative rat OCTN3 cDNA (XM_220427), which was predicted by a computational analysis of an annotated rat genomic sequence located in the chromosome 10 (q22) (NW_047334) using gene prediction methods, GNOMON (http://www.ncbi. nlm.nih.gov/genome/guide/gnomon.html) and TWINSCAN (http://genes.cs.wustl.edu/). The untranslated ~0.8 kb sequence from 2120 to the polyadenylation signal sequence was derived from the sequence of the chromosome 10 located after exon 10.
Structure of cartregulin protein and its subcellular localization.
Homology analysis of the 146 amino acid protein encoded by the cartregulin cDNA revealed that the first 131 amino acid of the protein was highly homologous to corresponding parts of rat OCTN1
[15] and OCTN2 [13] with 80% or 85% identity, respectively (Fig. 2) . The predicted cartregulin protein had a transmembrane domain (FQRLIFFLLSASII), which was identical to the conserved first domain of 11 or 12 transmembrane domains of rat OCTN1 or OCTN2, respectively. It also had three putative N-glycosylation sites conserved between rat OCTN1 and OCTN2. To clarify the size of cartregulin, we expressed it in COS-7 cells by transfection with the vector carrying cartregulin cDNA and analyzed by Western Blotting with a rabbit Ab raised against to the unique C-terminus amino acid sequence (QKFFPSQFELYSPP) of cartregulin. The protein expressed in COS-7 cells gave two bands with sizes of 27 kDa and 23 kDa, which were bigger than the expected size (16 kDa) of unmodified naked protein (Fig. 3) . This result suggested that cartregulin was post-translationallly modified, such as, glycosylation. To examine the intracellular localization of cartregulin protein, cartregulin tagged with GFP was expressed in CHO or COS-7 cells and its subcellular distribution was examined with a confocal microscopy. As shown in Fig. 4 , the subcellular distribution of the cartregulin protein in CHO cells was almost identical to that of ER, which was identified with anti KDEL Ab. Similar results were obtained for COS-7 cells (data not shown). These findings indicated that the cartregulin protein was localized in ER.
Tissue distribution of cartregulin mRNA.
The tissue distribution of cartregulin mRNA was examined by Northern blot analysis and RT-PCR.
The probe for Northern blot was a non-coding 195 bp sequence (18-213) of cartregulin cDNA, which was carefully designed to avoid cross-reaction with mRNAs for rat OCTN1, OCTN2 or the putative OCTN3. As shown in Fig. 5A , the ~3.0 kb mRNA corresponding to the cartregulin cDNA in size was detected in many tissues of rat. The mRNA was strongly expressed in the rat kidney and epididymis, moderately in the intestine and colon, and weakly in the brain, lung, heart and skeletal muscle, but it was undetectable in the liver, stomach, and spleen. In the testis, two mRNAs with different sizes (~2.3 kb and ~3.3 kb) were found, suggesting an occurrence of splicing variants of cartregulin mRNA. Essentially similar tissue distribution of cartregulin mRNA was obtained when examined by RT-PCR with a pair of primers that amplify the 195 bp sequence (18-213) specific for cartregulin mRNA (Fig. 5B ).
Functional characterization of cartregulin.
The high sequence homology of cartregulin to the part of OCTN1 or OCTN2 (Fig. 2) prompted us to test the possibility that the cartregulin has a transport activity for carnitine and acetylcarnitine.
The cartregulin cDNA ligated with a mammalian expression vector (pBK-CMV) driven by a cytomegalovirus promoter was transfected into COS-7 cells and the uptake of carnitine or acetylcarnitine was measured. Under our assay conditions, however, we were unable to demonstrate any transport activity of cartregulin for carnitine or acetylcarnitine, being consistent with the fact that cartregulin is expressed in ER but not in plasma membrane (Fig. 4) . Then, we examined the possibility that cartregulin may modulate the transport activity of OCTN2. When cartregulin was co-transfected with OCTN2, it enhanced the transport activity of OCTN2 for carnitine by about 2-fold (Fig. 6) . Similarly, cartregulin enhanced the transport activity of OCTN2 for acetylcarnitine by about 2-fold (data not shown). However, the enhancement of the transport activity of OCTN2 for carnitine or acetylcarnitine was not observed following transfection of the mock vector alone (not containing cartregulin cDNA) or the vector carrying rat OCTN1 cDNA, which was inactive for the transport activity for carnitine as reported previously [13] .
The mechanism of the enhancement of OCTN2 transport activity caused by cartregulin.
To understand how cartregulin enhances the transport activity of OCTN2, we first investigated the kinetic parameters (Km and Vmax values) of OCTN2 for carnitine or acetylcarnitine as described by Tamai et al. [11] . The Vmax represents the maximal transport activity at saturated concentrations of the substrate and the Km value (the Michaelis constant) is defined as the concentration of the substrate which gives the half activity of the Vmax. Our results indicated that the Km values of 12.6 ± 1.3 μM and 17.7 ± 1.7 μM for carnitine and acetylcarnitine, respectively, in cells expressing OCTN2 alone were not significantly changed by cartregulin (Km values of 11.1 ± 2.0 μM and 18.3 ± 1.4 μM in cells expressing OCTN2 and cartregulin). These Km values represent the mean ± S.E. from three independent experiments. In contrast, the Vmax values expressed as pmol/h/10 6 cells increased from 53 ± 5 to 90 ± 10 for carnitine and from 70 ± 8 to 110 ± 15 for acetylcarnitine. These results suggested that the increase in the transport activity of OCTN2 was not caused by an increase in its affinity for carnitine or acetylcarnitine but by an increase in the protein level of the transporter. To address this point, we carried out Western blot and analysed the protein level of OCTN2 with an Ab against rat OCTN2. When expressed in COS-7 cells, OCTN2 existed as three forms with different molecular sizes: 60 kDa, ~80 kDa and ~160 kDa (Fig. 7A) . The 60 kDa protein was likely to be the unmodified naked form of OCTN2, and the ~80 kDa protein was considered to be a post-translationally modified (e.g., glycosylation) form of OCTN2, and the ~160 kDa entity was probably a dimeric form of the ~80 kDa protein. The levels of the major 80 kDa and 160 kDa forms of OCTN2 (Figs. 7A and 7D) were significantly elevated by co-transfection of cartregulin cDNA in parallel with the enhancement of the transport activity of OCTN2 (Fig. 7C) . These findings clearly indicated that the increase in the transport activity of OCTN2 caused by cartregulin was due to an increase in protein levels of OCTN2 in COS-7 cells. To test whether the increase in protein levels of OCTN2 is caused by an increase in the level of OCTN2 mRNA, we measured the transcript by Northern blot. Following the co-expression of cartregulin, the level of OCTN2 mRNA increased to the same extent as that of OCTN2 protein (Figs. 7B and 7E ). These results demonstrated that the enhancement was due to an increase in the level of OCTN2 mRNA.
To determine whether the effect of cartregulin is specific for OCTN2, we examined the effect of cartregulin on levels of protein and mRNA for OCTN1 or ET A R, and found that these parameters were unaffected by co-expression of cartregulin (data not shown). These results indicated that the effect of cartregulin is specific for OCTN2.
In general, an elevation of mRNA level is explained by two mechanisms. One mechanism is an increase in the rate of transcription and the other is a stabilization of mRNA, that is, an inhibition of decay of mRNA. The transcription (synthesis of mRNA) of OCTN2 cDNA ligated with the eukaryotic expression vector, pBK-CMV, is under the control of a promoter of a cytomegalovirus and the transcription requires binding of endogenous transcription factors of transfected cells to the promoter sequence of the vector. These events occur in nucleus and therefore the vector should be transferred to nucleus for transcription of the OCTN2 cDNA [26] . Since cartregulin is localized in ER (Fig. 4) , it is unable to activate the transcription of OCTN2 by interacting directly with the promoter element or by interacting with the endogenous transcription factors in nucleus. Rather, it is plausible that cartregulin stabilizes OCTN2 mRNA in ER and thereby increases the mRNA levels of OCTN2, leading to an elevation in protein level of OCTN2. To test this idea, OCTN2 cRNA was injected into Xenopus oocytes alone or in combination with cartregulin cRNA and the uptake of acetylcarnitine into the oocytes was measured. As shown in Fig. 8 , there was no substantial uptake of acetylcarnitine into the oocytes injected with cartregulin cRNA or OCTN1, as compared with that into oocytes injected with tRNA alone. Notably, the uptake of acetylcarnitine via OCTN2 increased by about two-fold in oocytes injected with OCTN2 cRNA in combination with that for cartregulin, as compared with the uptake in oocytes injected with OCTN2 cRNA alone. Because the amount of injected OCTN2 cRNA is the same among oocytes (50 ng/oocyte), the enhancement of transport activity of OCTN2 is interpreted to reflect an elevation of OCTN2 protein resulting from stabilization of OCTN2 mRNA by cartregulin and a subsequent increase in the mRNA level. However, co-injection of cRNA for OCTN1 into oocytes was without effect on the uptake of acetylcarnitine via OCTN2. Thus, we concluded that cartregulin specifically stabilized OCTN2 mRNA and thereby increased OCTN2 expression.
DISCUSSION
In this study, we have isolated a new cDNA, cartregulin, from a rat brain cDNA library, which functions as an upregulator of OCTN2, a membrane transporter for carnitine and acetylcarnitine.
Homology analysis reveled that the cartregulin cDNA is a member of OCTN family. A significant part of cartregulin cDNA sequence was essentially identical to a part of the putative rat OCTN3 cDNA (XM_220427), which was predicted by computational analysis of an annotated rat genomic sequence (NW 047334), spanning ~73 kb in a locus of the chromosome 10 (10q22) (Fig. 1) . For example, the c-jun N-terminal kinase (JNK)-response element in the 5'-UTR plays a role in the stabilization of mRNAs for interleukin-2 and chemokine KC, and nucleolin and YB-1 are demonstrated to bind to the JNK-response element [23] . As for such elements in the 3'-UTR mRNA, the adenosine-uridine regions (AUUUA) or AU rich element (ARE) is identified for various mRNAs, and ELAV and AUF1 proteins are shown to interact with the ARE [21] . It is also reported that a C-rich element in the 3'-UTR of α-globin mRNA is critical for the stability of this long-lived mRNA and α-CP protein is demonstrated to bind to the element [24] . In addition to the 5'-UTR or 3'-UTR of mRNA, a part of the coding region of mRNA has been shown to be implicated in its stability. For example, the exon 3 region of c-myc mRNA is identified to protect the mRNA from nucleases, and a binding of a 70 kDa protein to the element is demonstrated [25] . Sequence analysis of cartregulin, however, indicated that neither of the JNK-element, the ARE-element or the C-rich element is present in the 5'-UTR or 3'-UTR of OCTN2 mRNA. These data suggest that a novel element in either 5'-UTR or 3'-UTR of OCTN2 mRNA is involved in the cartregulin-mediated stabilization of the mRNA. Alternatively, an element of the coding region of OCTN2 mRNA is responsible for the cartregulin-mediated stabilization. It is also possible that cartregulin may be indirectly involved in the stabilization of OCTN2 mRNA, where cartregulin associates with other effecter protein that interacts directly with the UTR or the coding element of OCTN2 mRNA. Analysis of the putative element of OCTN2 mRNA is in progress in our laboratory.
The mRNA-stabilizing action of cartregulin is specific for OCTN2 mRNA, because the levels of protein and mRNA for OCTN1 and ET A R were unaffected by cartregulin. Conversely, the stabilization of mRNA for OCTN2 is specific for cartregulin, because OCTN1 (an analog of cartregulin) showed no mRNA-stabilizing action. This specificity may be explained by the hypothesis that the stabilization of OCTN2 mRNA is attained through a specific interaction between cartregulin and an element of OCTN2 mRNA.
Of interest is that the tissue distribution of cartregulin mRNA (Fig. 5 ) differed from that of OCTN2 [11] ; the expression of cartregulin mRNA is undetectable in some organs such as the liver, spleen, and stomach, whereas OCTN2 mRNA is expressed ubiquitously in many organs. The most striking difference is observed in the skeletal muscle, where the expression of cartregulin is very low, being in contrast with the highest expression of OCTN2 among many tissues [11] . This non-parallel expression of cartregulin with OCTN2 indicates that the expression of cartregulin is controlled in a different way from that of OCTN2.
OCTN2 transports carnitine as well as acetylcarnitine. Not only carnitine plays an important role in transfer of long chain fatty acids from cytosol into mitochondria for β-oxidation, but also it has been recently shown that carnitine prevents injury of normal cells caused by a anti-caner drug, cisplatin [19] and inhibits hepatocarcinogenesis via protection of mitochondria [20] . Acetylcarnitine, on the other hand, has been attracting much attention because of its pharmacological effects on various neurological disorders such as age-dependent memory loss [6, 7] , Alzheimer-type dementia [8, 9] , and chronic fatigue syndrome [5] . Therefore, OCTN2 could be a therapeutic target for cancers and neurological diseases, and since cartregulin up-regulates the expression of OCTN2 as shown here, it could be an alternative therapeutic target for these diseases through enhancement of OCTN2
expression.
In conclusion, we were the first to isolate cartregulin cDNA as a new family member of OCTNs, and show a novel role of cartregulin in the regulation of OCTN2. With a better understanding of the regulatory mechanism, we hope to improve the treatment of a variety of diseases with carnitine or acetylcarnitine.
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